| scholarly article | Q13442814 |
| P356 | DOI | 10.1081/CRP-100108179 |
| P50 | author | Barbara Ensoli | Q21255143 |
| P2093 | author name string | Aurelio Cafaro | |
| P2860 | cites work | AIDS preclinical vaccine development: biennial survey of HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates | Q73262432 |
| Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa | Q73280230 | ||
| IgG surfaces as an important component in mucosal protection | Q73401401 | ||
| Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease | Q73470103 | ||
| Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime | Q74601718 | ||
| CD8-suppressor factor and beta-chemokine function as a complementary mechanism to cognate immunity | Q77323990 | ||
| Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS | Q77323993 | ||
| The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence | Q24561727 | ||
| Tat protein induces self-perpetuating permissivity for productive HIV-1 infection | Q24683211 | ||
| HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region | Q28252310 | ||
| Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system | Q28286009 | ||
| Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
| Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes | Q29616210 | ||
| Importance of the nef gene for maintenance of high virus loads and for development of AIDS | Q29618369 | ||
| Prognosis in HIV-1 infection predicted by the quantity of virus in plasma | Q29619980 | ||
| Cellular uptake of the tat protein from human immunodeficiency virus | Q29620627 | ||
| A new generation of animal cell expression vectors based on the Semliki Forest virus replicon | Q30014839 | ||
| Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene | Q33196552 | ||
| Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques | Q33490720 | ||
| Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. | Q33546852 | ||
| CD8+ cell-derived anti-human immunodeficiency virus inhibitory factor | Q33547164 | ||
| T lymphocyte responses in HIV-1 infection: implications for vaccine development | Q33711396 | ||
| Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival | Q33759097 | ||
| A rational basis for mucosal vaccination against HIV infection | Q33776167 | ||
| Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design | Q34158340 | ||
| The trans-activator gene of HTLV-III is essential for virus replication | Q34161962 | ||
| Applications of pox virus vectors to vaccination: an update | Q34403246 | ||
| Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. | Q34479873 | ||
| Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity | Q35130248 | ||
| Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. | Q35611863 | ||
| Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. | Q36011366 | ||
| A vaccine for HIV type 1: the antibody perspective | Q36037760 | ||
| Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies | Q36229742 | ||
| Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. | Q36363472 | ||
| Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization | Q36400299 | ||
| The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques | Q36401769 | ||
| Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein | Q36486560 | ||
| Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model | Q37164192 | ||
| Alphavirus-based expression vectors: strategies and applications | Q37250563 | ||
| Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus | Q38358591 | ||
| Molecular cloning and expression of rhesus macaque and sooty mangabey interleukin 16: biologic activity and effect on simian immunodeficiency virus infection and/or replication | Q39167093 | ||
| Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines | Q39360889 | ||
| Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. | Q39457063 | ||
| An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum | Q40398941 | ||
| Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice | Q41065891 | ||
| Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo | Q41071177 | ||
| Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure | Q41212897 | ||
| Sindbis virus vectors for expression in animal cells | Q41238586 | ||
| Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs | Q41266882 | ||
| Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. | Q41335848 | ||
| Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein | Q41349382 | ||
| Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma | Q41435232 | ||
| Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? | Q41717140 | ||
| Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients | Q41734588 | ||
| Vaccination with Rev and Tat against AIDS. | Q42543092 | ||
| Suppressive effect of antibody on processing of T cell epitopes | Q42941954 | ||
| Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants | Q42942996 | ||
| Sindbis virus: an efficient, broad host range vector for gene expression in animal cells | Q42991441 | ||
| Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. | Q43440882 | ||
| Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease | Q43582240 | ||
| Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. | Q43692324 | ||
| Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. | Q43984746 | ||
| Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization | Q44592013 | ||
| AIDS vaccine developments | Q45009094 | ||
| Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein | Q45298725 | ||
| Regulation of Cellular Gene Expression and Function by the Human Immunodeficiency Virus Type 1 Tat Protein | Q45734648 | ||
| Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 | ||
| Recombinant human CD40 ligand inhibits simian immunodeficiency virus replication: a role for interleukin- 16. | Q45745787 | ||
| Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations | Q45749670 | ||
| Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen. | Q45750307 | ||
| Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice | Q45750778 | ||
| Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. | Q45753829 | ||
| Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group | Q45756090 | ||
| Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys | Q45759814 | ||
| Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. | Q45761030 | ||
| Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. | Q45761033 | ||
| Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors | Q45772545 | ||
| Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees | Q45776493 | ||
| Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration | Q45783638 | ||
| Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. | Q45785662 | ||
| A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. | Q45788200 | ||
| Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). | Q45838520 | ||
| Efficacy studies on a canarypox-rabies recombinant virus | Q45852734 | ||
| Tat toxoid as a component of a preventive vaccine in seronegative subjects | Q45857178 | ||
| Progress towards a vaccine to prevent sexual transmission of HIV. | Q46045275 | ||
| Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy | Q46147703 | ||
| Vaccine developments | Q46448539 | ||
| Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients | Q47918537 | ||
| In vivo migration and function of transferred HIV-1-specific cytotoxic T cells | Q47995100 | ||
| HIV-1 neutralizing antibodies: how full is the bottle? | Q52844823 | ||
| Fusion-competent vaccines: broad neutralization of primary isolates of HIV | Q56765810 | ||
| Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | Q56774528 | ||
| AIDS vaccine developments | Q56838054 | ||
| Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA | Q56930699 | ||
| AIDS vaccine developments | Q59028032 | ||
| Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine | Q59511395 | ||
| Immunotherapy for recurrent miscarriage | Q61837916 | ||
| Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope | Q64134477 | ||
| Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques | Q71169973 | ||
| Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection | Q71542174 | ||
| Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques | Q71802849 | ||
| Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination | Q72629529 | ||
| Enhancement of disease by neutralizing antiviral antibodies in the absence of primed antiviral cytotoxic T cells | Q72650455 | ||
| Alloimmunization to prevent AIDS? | Q72761700 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 293-327 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Clinical Research and Regulatory Affairs | Q15758058 |
| P1476 | title | NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS* | |
| P478 | volume | 18 |
| Q51998598 | Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. | cites work | P2860 |
Search more.